

## TER and Rating Sample

## SGA- Monthly Report On Total Expense Ratio of Funds

ISIN	Name of the Fund	Cur.	TER (Current)	Date (Current)	TER (Previous)	Date (Previous)	Remarks
GB0008549288	CL (Gue) European High Yield Bond -B-	EUR	1.25	2/29/2008	1.13	8/31/2007	We have found TER from Factsheet and Semi-annual report.
LU0104884860	Pictet Funds (LUX) SICAV - Water Cap.-P-	EUR	1.90	1/31/2008	1.90	6/30/2007	We have found TER from Factsheet and Annual report.
US4642868305	iShares MSCI Malaysia Index Fund	USD	0.52	12/31/2007	0.51	8/31/2007	We have found TER from Factsheet and Interim report.
GB0008474453	CL (Gue) Finance Equity Fund -B-	EUR	2.09	2/29/2008	2.08	8/31/2007	We have found TER from Factsheet and Semi-annual report.
FR0000941312	UBAM Convertibles Europe SICAV Cap. 3D	EUR	1.20	12/31/2007	1.19	12/31/2006	We have found TER from Annual report with the help of IR desk.
GB0009580241	CL (Gue) Luxury Goods Equity Fund -B-	EUR	2.03	2/29/2008	2.03	8/31/2007	We have found TER from factsheet and Semi-annual report.
CH0012115264	CL (CH) Cat Bond Fund EUR-Class	EUR	1.75	12/31/2007	1.75	6/30/2007	We have found TER from Factsheet and Semi-annual report.
CH0012115272	CL (CH) Cat Bond Fund USD-Class	USD	1.75	12/31/2007	1.75	6/30/2007	We have found TER from Factsheet and Semi-annual report.
LU0128522157	Franklin Templeton Inv - Asia Growth -A-	USD	2.18	12/31/2007	2.24	6/30/2007	We have found TER from AMC's website and Annual report. For Previous TER: calculated TER using Lipper premium module.
LU0129412341	JPMF - Global CV Fund -A- Distrib.	EUR	1.65	6/30/2007	1.65	6/30/2006	We have found TER from Annual Report and Interim Report.
LU0130191181	CL (Lux) Biotechnology Equity Fund -IB-	USD	1.57	12/31/2007	1.57	9/30/2007	We have found TER from factsheet. For Previous TER: calculate TER using Lipper premium module.
LU0130192072	CL (Lux) Technology Equity Fund -IB-	USD	0.87	6/30/2007	1.71	12/31/2006	We have found TER from factsheet. For Previous TER: calculate TER using Lipper premium module.

## SGA - Monthly Report on Bond Ratings

ISIN	Security Name	Rating Snapshot		
		S&P	Moody's	Fitch
FR0000497398	5 5/8 % CFF 99/10	AAA	Aaa	AAA
FR0000497430	5 1/2 % Dexia Municipal Agency 99/10	AAA	Aaa	AAA
XS0107657222	6 5/8 % FKI Plc 00/10 Sen.	BB	Ba3	N.A.
DE0002811791	5 1/2 % LKB Baden-Wuerttemberg 00/10	AA+	Aaa	N.A.
DE0001591089	6 % Deutsche Bahn Finance 00/10	AA	Aa1	N.A.
US912810EQ77	6 1/4 % United States of America:1993-15	AAA	Aaa	N.A.
CH0011016042	4 3/8 % LBK Hessen-Thuringen 00/08	AA	Aaa	AAA
XS0114295560	8 1/4 % Russische Föderation 00/10 Reg-S	BBB+	Baa2	N.A.
DE0001007037	5 3/4 % LB Rheinland-Pfalz 00/11	AAA	Aaa	AAA
DE0003356911	6 % Hypo Real Estate Bank AG 00/15	AAA	Aaa	AAA
CH0011510556	4 3/8 % GECC 00/12	AAA	Aaa	N.A.
CH0011761746	3 3/4 % LBk Hessen-Thüringen Giro 01/11	AA	Aaa	AAA
DE0002574613	5 1/4 % Hypothekenbank in Essen 01/11	AAA	Aaa	AAA
DE0001016822	5 1/4 % Dexia Kommunalbank AG 01/13	AAA	N.A.	N.A.
XS0125133644	5 3/4 % Barclays Bank PLC 01/11	AA-	Aa2	AA
DE0003510541	5 1/4 % Deutsche Pfandbriefbank 01/11	AAA	Aaa	AAA
NL0000102606	5 % Koenigreich der Niederlande 01/11	N.A.	Aaa	AAA
XS0127563301	5 3/8 % Citibank CC Issuance 01/11 (13)	AAA	Aaa	AAA
XS0130171159	6 3/8 % CS Group Fin. (Gue) 01/13 s.o.	A	Aa3	A+
FR000187635	5 3/4 % Republik Frankreich 01/32	AAA	Aaa	N.A.
CH0012576150	4 1/4 % Credit Suisse Guernsey Br. 01/11	N.A.	Aa3	N.A.
XS0138244446	5 7/8 % Lafarge SA 01/08	BBB	Baa2	BBB
US097014AG93	6 1/2 % Boeing Capital Corp 01/12 SrN	A+	A2	A+
XS0138467401	Swiss Re Am. 01/11 CV on Swiss Re s.o.	A	A1	N.A.

FOR COMPLETE SAMPLE REPORT PLEASE CONTACT US ON

Phone: Pune: +91 020 25661897

Zurich: +41 44 724 41 92

Email: [contact@sganalytics.com](mailto:contact@sganalytics.com)

OR

Visit our website

[www.sganalytics.com](http://www.sganalytics.com)

DISCLAIMER: SG Analytics reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information, which is incomplete or incorrect, will therefore be rejected. No part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Company Report.